1) Biosafety directives
Biosafety directives provide regulated parties with the customized containment requirements for activities with a specific pathogen or group of pathogens when the containment level does not align with the risk group.
This Directive provides the minimum containment requirements for the safe handling of MTBC, including activities that can be carried out safely at CL2 with additional biosafety requirements. The Directive has been updated to reflect new MTBC strains and the requirements of the Canadian Biosafety Standard (CBS).
The Public Health Agency of Canada, in collaboration with an Ad hoc Expert Group for HIV and HTLV, has developed a Biosafety Directive for HIV and HTLV-1 which provides a comprehensive overview of the updated containment level requirements for laboratories working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is now available to stakeholders and other interested parties.
2) Biosafety advisories
are developed when the data obtained from a Risk Assessment of a new or emerging pathogen of interest indicates that new physical and/or operational requirements are required to work with the pathogen safely. The new operational and/or physical requirements need to be disseminated to interested parties as soon as possible for the safe handling of the material. In order to ensure accuracy, biosafety advisories are reviewed frequently and updated when more information becomes available.
3) Biosafety notifications
are developed when the data obtained from a Risk Assessment for a particular pathogen indicates that no changes will be required to the pre-existing physical and operational requirements. The notification is created to emphasize these requirements to limit the spread of the particular pathogen.